More recently, Djenidi et al. reported that CD8+CD103+ tumour infiltrating T cells are a prognostic factor for survival in NSCLC [16] and the success of checkpoint immunotherapy trials indicates that T cells can play an important role in disease control [1]. This evidence concerns the gene CD8A and neoplasm.